Evidence map›Paper›PMID 28214954›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2017

Association of Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile with the risk of primary open angle glaucoma.

Jose Navarro-Partida, Abril Bernardette Martinez-Rizo, Pedro Ramirez-Barrera, Jesus Bernardino Velazquez-Fernandez, Veronica A Mondragon-Jaimes, Arturo Santos-Garcia, Veronica Benites-Godinez

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Restoring AIBP expression in the retina provides neuroprotection in glaucoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  6. Article
  7. Review
  8. Single-nucleotide polymorphisms ofExperimental biology and medicine (Maywood, N.J.) · 2023
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Tenascins in Retinal and Optic Nerve Neurodegeneration.Frontiers in integrative neuroscience · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jose Navarro-PartidaTecnológico de Monterrey, División de Biotecnología y Salud, Campus Guadalajara, Guadalajara, Jalisco, México. josenavarro@itesm.mx.
Abril Bernardette Martinez-RizoUniversidad Autónoma de Nayarit, Tepic, Nayarit, México.
Pedro Ramirez-BarreraUniversidad Autónoma de Nayarit, Tepic, Nayarit, México.
Jesus Bernardino Velazquez-FernandezUniversidad Autónoma de Nayarit, Tepic, Nayarit, México.
Veronica A Mondragon-JaimesUniversidad Autónoma de Nayarit, Tepic, Nayarit, México.
Arturo Santos-GarciaTecnológico de Monterrey, División de Biotecnología y Salud, Campus Guadalajara, Guadalajara, Jalisco, México.
Veronica Benites-GodinezInstituto Méxicano del Seguro Social, Delegación, Nayarit, México.
Universidad Autónoma de Nayarit · MXTecnológico de Monterrey · MXMexican Social Security Institute · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeToll-like receptor 4 (TLR4) is a transmembrane receptor that mediates immune responses to exogenous and endogenous ligands. Previously, non-coding single nucleotide polymorphisms (SNPs) in the TLR4 gene were related to primary open angle glaucoma (POAG). This study was undertaken to investigate whether coding TLR4 Asp299Gly (rs4986790 A/G) and Thr399Ile (rs4986791 C/T) are associated with POAG in a Mexican population.

methodsOne hundred and eighty-seven unrelated Mexican patients with POAG (94 men and 95 women; mean age 66.49 ± 14.3 years) and 109 control subjects (40 men and 69 women; age, 63.28 ± 7.93 years) were included. SNPs Asp299Gly (rs4986790 A/G) and Thr399Ile (rs4986791 C/T) were genotyped by a Taqman® Allelic Discrimination Assayand. Allelic, genotypic, haplotypic, and model-based (dominant, recessive, and codominant) associations of the SNPs with POAG were analyzed using Chi-squared tests or Fisher exact tests and logistic regression.

resultsStrong linkage disequilibrium was observed among the SNPs (D' = 0.8692), which were located in one haplotype block. With respect to allelic diversity, the minor allele of both SNPs generates a significantly increased risk of POAG. The minor allele of Asp299Gly conferred the highest increased risk of POAG (P = 0.0054, OR = 4.47, 95% CI = 1.46-13.70). With regard to genotypic diversity, individuals carrying the minor allele of Asp299Gly and Thr399Ile had a significant increased risk for POAG with OR of 4.47 (P = 0.054, 95% CI = 1.30-15.35) and 3.5, respectively (P = 0.012, 95% CI = 1.17-10.44). Haplotype analysis was non-significant.

conclusionsTLR4 coding SNPs Asp299Gly and Thr399Ile might be used as genetic susceptibility alleles for POAG in Mexican population. Our findings support the role of TLR4 in the pathophysiology of glaucoma.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAgedAllelesDNAFemaleGene FrequencyGenotypeGlaucoma, Open-AngleHumansMaleMiddle AgedReal-Time Polymerase Chain ReactionToll-Like Receptor 4DNATLR4 protein, humanToll-Like Receptor 4Asp299GlyPolymorphismsPrimary open angle glaucomaThr399IleToll-like receptor 4

Identifiers

PMID28214954
OpenAlexW2588266763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.